Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Legend Biotech ( (LEGN) ) just unveiled an announcement.
On October 14, 2025, Legend Biotech announced that its product CARVYKTI® achieved approximately $524 million in net trade sales for the quarter ending September 30, 2025. This announcement highlights the product’s significant market performance, although the sales figures are preliminary and subject to further financial review. The impact on Legend Biotech’s operations and industry positioning is notable, as it underscores the company’s growing influence in the biotechnology sector.
The most recent analyst rating on (LEGN) stock is a Buy with a $76.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.
Spark’s Take on LEGN Stock
According to Spark, TipRanks’ AI Analyst, LEGN is a Neutral.
Legend Biotech’s overall stock score is driven by its financial performance challenges, including ongoing losses and cash flow issues. Despite positive sentiment from the earnings call and strategic growth initiatives, the stock’s bearish technical indicators and negative valuation metrics weigh heavily on its score. The company’s future prospects hinge on achieving operational efficiency and profitability.
To see Spark’s full report on LEGN stock, click here.
More about Legend Biotech
Legend Biotech Corporation operates in the biotechnology industry, focusing on the development and commercialization of innovative cell therapies. The company is particularly known for its CARVYKTI® product, which is a key component of its strategic collaboration with Janssen Biotech.
Average Trading Volume: 1,238,530
Technical Sentiment Signal: Sell
Current Market Cap: $5.85B
For a thorough assessment of LEGN stock, go to TipRanks’ Stock Analysis page.